The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Throughout recorded history, attempts at producing a state of general anesthesia can be traced back to the writings of ancient Sumerians, Babylonians, Assyrians, Akkadians, Egyptians, Persians, Indians, and Chinese. Despite significant advances in anatomy and surgical techniques during the Renaissance, surgery remained a last-resort treatment largely due to the pain associated with it. This limited surgical procedures to addressing only life-threatening conditions, with techniques focused on speed to limit blood loss. All of these interventions carried high risk of complications, especially death. Around 80% of surgeries led to severe infections, and 50% of patients died either during surgery or from complications thereafter. Many of the patients who were fortunate enough to survive remained psychologically traumatized for the rest of their lives. However, scientific discoveries in the late 18th and early 19th centuries paved the way for the development of modern anesthetic techniques. The 19th century was filled with scientific advancements in pharmacology and physiology. During the 1840s, the introduction of diethyl ether (1842), nitrous oxide (1844), and chloroform (1847) as general anesthetics revolutionized modern medicine. The late 19th century also saw major advancements to modern surgery with the development and application of antiseptic techniques as a result of the germ theory of disease, which significantly reduced morbidity and mortality rates.
=== Works cited === Adams, John, ed. (1805). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Andrew, Christopher (2018). Secret World: A History of Intelligence. Yale University Press. ISBN 978-0-300-24052-8. Arnold, James R. (1995). Napoleon Conquers Austria: The 1809 Campaign for Vienna. Greenwood Publishing Group. ISBN 978-0-275-94694-4. Bell, David Avrom (2007). The First Total War: Napoleon's Europe and the Birth of Warfare as We Know it. Houghton Mifflin Harcourt. ISBN 978-0-618-34965-4. Black, Jeremy (2009). The War of 1812 in the Age of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4078-0. Briggs, Asa (1959). The Making of Modern England, 1783–1867: The Age of Improvement. Harper & Row. Bryant, Arthur (1944). Years of Victory, 1802–1812. Collins. Burke, Edmund (1808). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Canales, Esteban (2004), 1808–1814: demografía y guerra en España (PDF) (in Spanish), Autonomous University of Barcelona, retrieved 3 May 2017 Chandler, David G. (1966). The Campaigns of Napoleon. Scribner. ISBN 978-0-02-523660-8. Clodfelter, Micheal (2017). Warfare and Armed Conflicts: A Statistical Encyclopedia of Casualty and Other Figures, 1492–2015 (4th ed.). McFarland. ISBN 978-1-4766-2585-0. Desan, Suzanne; Hunt, Lynn; Nelson, William Max (2013). The French Revolution in Global Perspective. Cornell University Press. ISBN 978-0-8014-6747-9. Dwyer, Philip (2013). Citizen Emperor: Napoleon in Power. Esdaile, Charles (2009).
==== Antibodies ==== Two monoclonal antibodies have been approved to target amyloid beta – donanemab and lecanemab – but as of 2025, their role in treatment is uncertain because of side effects, questions about efficacy, and cost. Lecanemab is approved in the US, including a boxed warning about amyloid-related imaging abnormalities. A 2026 meta-analysis found that anti-amyloid antibodies have no effect in the treatment of Alzheimer's disease. A 2026 Cochrane review found no effect or at best small effect. Anti-amyloid antibodies may cause harmful adverse effects and have been shown to slow disease progression only in individuals with "early and mild AD, and cognitive benefits were often marginal."
Long term neuropsychiatric difficulties are increasingly recognized (49 studies so far, especially obsessive-compulsive disorder but also attention-deficit hyperactivity disorder, affective disorders, tic disorders, executive function disturbances, psychotic features, and language impairment). Heart involvement improves in about a third of cases (whether silent or not).
=== Mechanism of action === When it is administered intravenously, adenosine causes transient heart block in the atrioventricular (AV) node. This is mediated via the A1 receptor, inhibiting adenylyl cyclase, reducing cAMP and so causing cell hyperpolarization by increasing K+ efflux via inward rectifier K+ channels, subsequently inhibiting Ca2+ current. It also causes endothelial-dependent relaxation of smooth muscle as is found inside the artery walls. This causes dilation of the "normal" segments of arteries, i.e. where the endothelium is not separated from the tunica media by atherosclerotic plaque. This feature allows physicians to use adenosine to test for blockages in the coronary arteries, by exaggerating the difference between the normal and abnormal segments. The administration of adenosine also reduces blood flow to coronary arteries past the occlusion. Other coronary arteries dilate when adenosine is administered while the segment past the occlusion is already maximally dilated, which is a process called coronary steal. This leads to less blood reaching the ischemic tissue, which in turn produces the characteristic chest pain.
Sources: en.wikipedia.org
=== Variations === Semi-solid and soft nanoparticles have been produced. A prototype nanoparticle of semi-solid nature is the liposome. Various types of liposome nanoparticles are currently used clinically as delivery systems for anticancer drugs and vaccines. The breakdown of biopolymers into their nanoscale building blocks is considered a potential route to produce nanoparticles with enhanced biocompatibility and biodegradability. The most common example is the production of nanocellulose from wood pulp. Other examples are nanolignin, nanochitin, or nanostarches. Nanoparticles with one half hydrophilic and the other half hydrophobic are termed Janus particles and are particularly effective for stabilizing emulsions. They can self-assemble at water/oil interfaces and act as pickering stabilizers. Hydrogel nanoparticles made of N-isopropylacrylamide hydrogel core shell can be dyed with affinity baits, internally. These affinity baits allow the nanoparticles to isolate and remove undesirable proteins while enhancing the target analytes.
== Role in development and regulation == Tyrosine-protein kinase CSK is involved in the following developmental, metabolic, and signal transduction cascades: Adherens junction organization, blood coagulation, brain development, cell differentiation, cell migration, cellular response to peptide hormone stimulus, central nervous system development, epidermal growth factor receptor signaling pathway, innate immune response, epithelium morphogenesis, regulation of bone resorption, negative regulation of cell proliferation, negative regulation of ERK1 and ERK2 cascade, negative regulation of Golgi to plasma membrane protein transport, negative regulation of interleukin-6 production, negative regulation of kinase activity, negative regulation of low-density lipoprotein particle clearance, negative regulation of phagocytosis, dendrocyte differentiation, peptidyl-tyrosine autophosphorylation, platelet activation, positive regulation of MAP kinase activity, regulation of cell proliferation, regulation of cytokine production, regulation of Fc receptor mediated stimulatory signaling pathway, T cell costimulation, T cell receptor signaling pathway.
=== Embryonic development === Wnt signaling plays a critical role in embryonic development. It operates in both vertebrates and invertebrates, including humans, frogs, zebrafish, C. elegans, Drosophila and others. It was first found in the segment polarity of Drosophila, where it helps to establish anterior and posterior polarities. It is implicated in other developmental processes. As its function in Drosophila suggests, it plays a key role in body axis formation, particularly the formation of the anteroposterior and dorsoventral axes. It is involved in the induction of cell differentiation to prompt formation of important organs such as lungs and ovaries. Wnt further ensures the development of these tissues through proper regulation of cell proliferation and migration. Wnt signaling functions can be divided into axis patterning, cell fate specification, cell proliferation and cell migration.
In March 2003, 2–325 of the 2nd BCT was attached to the 75th Ranger Regiment as part of a special operations task force to conduct a parachute assault to seize Saddam International Airport, part of Operation Iraqi Freedom. On 21 March 2003, Company D, 2-325 crossed the Saudi Arabia–Iraq border as part of Task Force Hunter to escort HIMARS artillery systems to destroy Iraqi artillery batteries in the western Iraqi desert. Upon cancellation of the parachute assault to seize the airport, the battalion returned to its parent 2nd Brigade at Talil Airfield near An Nasariyah, Iraq. The 2nd Brigade then conducted operations in Samawah, Fallujah, and Baghdad. The brigade returned to the United States by the end of February 2004. The early days of the 82nd Airborne's participation in the deployment were chronicled by embedded journalist Karl Zinsmeister in his 2003 book Boots on the Ground: A Month with the 82nd Airborne in the Battle for Iraq. In April 2003, according to Human Rights Watch, soldiers from a subordinate unit, the 1st battalion of the 325th Infantry, allegedly fired indiscriminately into a crowd of Iraqi civilians protesting their presence in the city of Fallujah, killing and wounding many civilians. The battalion suffered no casualties. The 3rd Brigade deployed to Iraq in the summer, redeploying to the US in spring 2004. The 1st Brigade deployed in January 2004. The last units of the division left by the end of April 2004. The 2nd Brigade deployed on 7 December 2004 to support the free elections and returned on Easter Sunday in 2005.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.